A review of the RADIANCE-HTN global clinical trial programme: a focus on the TRIO cohort

Sponsored by ReCor Medical

Facilitator: A. Kirtane

Chatmaster: M.D. Lobo

Summary

Watch this session presented by Ajay Kirtane, Melvin David Lobo and Felix Mahfoud in order to review a history of the field and the recent clinical advancements in renal denervation with the Paradise Ultrasound RDN system, to further examine the recently announced results from RADIANCE-HTN TRIO (blinded, sham-controlled, powered to demonstrate BP lowering effectiveness at two months), and to review expert perspectives on what this means for hypertension management.

View the EuroPCR 2021 Expert Interview of this session on "RADIANCE-HTN TRIO: what does this mean for the treatment of hypertension?".

Learning Objectives

To review a history of the field and the recent clinical advancements in renal denervation with the Paradise Ultrasound RDN system
To further examine the recently announced results from RADIANCE-HTN TRIO (blinded, sham-controlled, powered to demonstrate BP lowering effectiveness at two months)
To review expert perspectives on what this means for hypertension management